Nektar Restructures A Second Time, Focusing Squarely On Immunology

A year after reducing headcount by 70%, Nektar is trimming another 60% and looking to partner out cancer candidate NKTR-255 to focus on rezpeg for atopic dermatitis, with or without Lilly’s help.

severing ties and boycott concept
Nektar slashed headcount to push its cash runway to 2026

For the second time in just under a year, Nektar Therapeutics is restructuring, this time reducing headcount roughly 60% to about 55 people at its San Francisco headquarters, putting internal R&D emphasis on immunology and seeking to partner out its lead cancer candidate, the Phase II interleukin-15 (IL-15) receptor agonist NKTR-255. The biotech said on 17 April that it will prioritize development of IL-2-targeted rezpegaldesleukin (rezpeg) in autoimmune and inflammatory conditions regardless of whether partner Eli Lilly and Company continues its participation.

[Sidebar#SC146286]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.